Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients

Cancer Detection and Prevention

Volumn 26, Issue 1, 2002, Pages 42-49

  Levičar, Nataša ^a   Kos, Janko ^b,c   Blejec, Andrej ^a   Golouh, Rastko ^d   Vrhovec, Ivan ^d   Frkovič Grazio, Snježana ^d   Lah, Tamara T ^a  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

^c KRKA D D   (Slovenia)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Breast cancer; Cathepsin B; Cathepsin L; PAI 1; Stefin A; Stefin B; Urokinase (u PA)

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN L; CSTA PROTEIN, HUMAN; CYSTATIN; CYSTATIN B; CYSTEINE PROTEINASE; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; STEFIN A; TUMOR MARKER; UROKINASE;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; HUMAN; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSIN B; CATHEPSINS; CYSTATINS; CYSTEINE ENDOPEPTIDASES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036947460     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00015-6     Document Type: Article

References (45)

1. Schmitt M, Janicke F. Graeff H. Tumor-associated proteases. Fibrinolysis 1992;6:3-26.
2. Sloane BF, Moin K, Lah TT, Regulation of lysosomal endopeptidases in malignant neoplasia. In: Pretlow TG, Pretlow TP, editors. Biochemical and molecular aspects of selected cancers. New York: Academic Press, 1994. p. 411-72.
3. Lah TT, Buck MR, Honn KV, et al. Degradation of laminin by human tumor cathepsin B. Clin Exp Metastasis 1989;7:461-8.
4. Buck MR, Karustis DG, Day NA, et al. Degradation of extracellular matrix proteins by human cathepsin B from normal and tumor tissues. Biochem J 1992;282:273-8.
5. Weiss RE, Liu BCS, Ahlering TE, et al. Mechanism of human bladder tumor invasion: role of protease cathepsins. Br J Urol 1990;144:798-804.
6. Kobayashi H, Moniwa N, Sugima M, et al. Effects of membrane-associated cathepsin B on the activation of receptor-bound pro-urokinase and subsequent invasion of reconstituted basement membrane. Biochim Biophys Acta 1993;1178:55-62.
7. Ren WP, Sloane BF. Cathepsins D and B in breast cancer. In: Dickson RE, Lippman ME, editors. Breast cancer: mammary tumor cell cycle differentiation and metastasis. Boston: Kluwer Academic Publishers, 1996. p. 325-51.
8. Lah TT, Kokalj-Kunovar M, Štrukelj B, et al. Stefins and lysosomal cathepsins B in human breast carcinoma. Int J Cancer 1992;50:36-44.
9. Lah TT, Calaf G, Kalman E. et al. Cathepsins D, B and L in human breast carcinoma and transformed cells. Biol Chem 1995;376:357-63.
10. Thomssen C, Schmitt M, Goretzki L, et al. Prognostic value of the cysteine proteases cathepsins B and L in human breast carcinoma. Clin Cancer Res 1995;1:741-6.
11. Lah TT, Kos J, Blejec A, et al. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of disease. Pathol Oncol Res 1997;3:89-99.
12. Foekens JA, Kos J, Peters HA, et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998;16:1013-21.
13. Lah TT, Čerček M, Blejec A, et al. Cathepsin B a prognostic indicator in lymph node negative breast carcinoma patients: comparison with cathepsin D, cathepsin L and other clinical indicators. Clin Cancer Res 2000;6:578-84.
14. Budihna M, Strojan P, Šmid L, et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem 1996;377:385-90.
15. Ebert W, Knoch H, Werle B, et al. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 1994;14:895-900.
16. Kos J, Lab TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis diagnosis and therapy in cancer (review). Oncol Rep 1998;5:1361-439.
17. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997;378:141-50.
18. Järvinen M, Rinne A, Hopsu-Havu VK. Human cystatins in normal and diseased tissues - a review. Acta Histochem 1987;82:5-18.
19. Shiraishi T, Mori M, Tanka S, et al. Identification of cystatin B in human esophageal carcinoma, using differential displays in which gene expression is related to lymph node metastasis. Int J Cancer 1998;2:175-8.
20. Brünner N, Pyke C, Hansen CH, et al. Urokinase plasminogen activator (u-PA) and its type-1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 1994;71:299-309.
21. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
22. Duffy MJ, Duggan C, Maguire T, et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein 1996;49:85-93.
23. Danö K, Andreasen PA, Gröndahl-Hansen J, et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
24. Jänicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type-1. Cancer Res 1994;54:2527-30.
25. Gröndahl-Hansen J, Hilsenbeck SG, Christensen IJ, et al. Prognostic significance of PAI-1 and u-PA in cytosolic extracts obtained from node positive breast cancer patients. Breast Cancer Res Treat 1997;43:153-63.
26. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2789 breast cancer patients. Cancer Res 2000;60:636-43.
27. UICC: TNM classification of malignant tumors. Berlin: Springer, 1992.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from large study with long-term follow-up. Histopathology 1991;19:403-10.
29. EORTC Breast Cancer Cooperative Group: revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-5.
30. Kos J, Šmid A, Krašovec M, et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 1995;376:401-5.
31. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Star Assoc 1958;53:457-81.
32. Cox DR. Regression models of life tables. J R Star Soc 1972;34:187-220.
33. Sloane BF, Rozhin J, Krepela E, et al. The malignant phenotype and cysteine proteinases. Biomed Biochim Acta 1991;50:549-54.
34. Sameni M, Elliott E, Ziegler G, et al. Cathepsins B and D are localized at surface of human breast cancer cells. Pathol Oncol Res 1995;1:43-53.
35. Ulbricht B, Henny H, Horstmann H, et al. Influence of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) on the localization of cathepsin B and cathepsin L in human lung tumor cells. Eur J Cell Biol 1997;74:294-301.
36. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the pro-enzyme urokinase-type plasminogen activator (pro-(u-PA)). J Biol Chem 1991;266:5147-52.
37. Harbeck N, Dettmar P, Thomssen C, et al. Prognostic impact of tumor biological factors on survival in node negative breast cancer. Anticancer Res 1998;18:2187-97.
38. Thomssen C, Oppelt P, Jänicke F, et al. Identification of low-risk node negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res 1998;18:2173-80.
39. Prechtl A, Harbeck N, Thomssen C, et al. Tumor-biological factors u-PA and PAI-1 as stratification criteria of a multi-centre adjuvant chemotherapy trial in node negative breast cancer. Int J Biol Markers 2000;15:73-9.
40. Saad Z, Bramwell VHC, Wilson SM, et al. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998;351: 1170-3.
41. Dehrmann FM, Elliott E, Dennison C, et al. Reductive activation markedly increases the stability of cathepsins B and L to extracellular ionic conditions. Biol Chem 1996;377:391-4.
42. Kuopio T, Kankaanranta A, Jalava P. Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res 1998;58:432-6.
43. Kos J, Krašovec M, Cimerman N, et al. Cysteine protease inhibitors stefin A, stefin B and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000;6:505-11.
44. Ebert E, Werle B, Julke B, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997:421:259-65.
45. Knoch H, Werle B, Ebert W, et al. Imbalance between cathepsin B and cysteine proteinase inhibitors of prognostic significance in human lung cancer. Int J Oncol 1994;5:77-85.